Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions

(University of Texas M. D. Anderson Cancer Center) For patients with non-small cell lung cancers marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of patients in a Phase I/II trial.